We've Partnered With LECOM to Further Our Research
BIOSCENT DX ANNOUNCES NEW RESEARCH COLLABORATION WITH LECOM IN FIGHT AGAINST BREAST CANCER
Myakka City, Fla – BioScent DX, Inc. announced today that it has entered into a research collaboration agreement with Lake Erie College of Osteopathic Medicine in Bradenton, Florida. Through the agreement, BioScent and LECOM will aim to leverage canine scent detection to provide an effective, non-invasive means of screening for breast cancer.
BioScent DX has been conducting research and testing into canines’ ability to detect cancer in human breath, saliva, and blood at its laboratory in Myakka City, Florida. With the addition of the LECOM students and faculty leadership, BioScent will be able to accelerate its efforts in this groundbreaking field.
“We’ll provide the scientific aspect of this project to reinforce what BioScent is doing and also to see if we can take the testing further,” said Thomas Quinn, DO, LECOM faculty member.
Dogs have hundreds of millions more scent receptors than humans and the olfactory lobe of their brain is about 40 times larger, making their sense of smell thousands of times stronger than that of a person. Humans have long leveraged dogs’ extraordinary scent detection capabilities for tasks from hunting to explosive and narcotic detection. BioScent and LECOM aim to bring these capabilities into the clinical realm.
“Dogs’ ability to identify human samples positive for cancer is remarkable,” said Heather Junqueira, Lead Researcher, BioScent DX. “We are confident with LECOM onboard we’ll be able to expedite our efforts to bring these lifesaving capabilities to market.”
Previous studies have reported dogs to perform with as high as 99% accuracy detecting cancer from human samples. Harnessing these capabilities in a clinical setting would provide women with a diagnostic test for breast cancer that is less invasive and more accurate than a traditional mammogram.
About BioScent DX:
BioScent DX is utilizing canine scent detection to develop a non-invasive screening method for breast cancer and similar life threatening diseases. Through research and development of these capabilities, BioScent DX will offer patients a cost effective, simple yet highly accurate method to identify and eradicate diseases.
For more information, visit www.bioscentdx.com